Skip to main content
All
Stories
Press Releases
Documents
Events
Updates
Other
Press shift tab to select search category
Loading...
Newsroom
< Back
Newsroom
Press Releases
Media Updates
Media Resources
Media Contacts
Subscribe
Investors
< Back
Investors
Investors
Financial Results
Annual Reports & Regulated Information
Investor Events & Financial Calendar
Shareholder Information
Subscribe
Ratings & Bonds
Careers
< Back
Careers
Careers
Working at Ipsen
Culture
Job Search
Contacts
< Back
Contacts
Contacts
Our Locations
Report Side Effects
Subscribe
All
Stories
Press Releases
Documents
Events
Updates
Other
Press shift tab to select search category
X
Loading...
English EN
Français FR
EN
English
EN
Français
FR
Global
< Back
Global
EN
FR
Annual Report
EN
FR
Americas
Asia Pacific
Europe
Middle East & Africa
United States
Brazil
Canada
Mexico
Australia
China
Singapore
South Korea
Japan
Belgium
Ukraine
UK
Germany
France
Nordics
Greece
Italy
Netherlands
Spain
Poland
Russia
Czech Republic
Switzerland
Austria
UAE & Gulf
Saudi Arabia
Home
Company
< Back
Company
Company
Leadership
History
Fondation Ipsen
Expertise
< Back
Expertise
Oncology
Rare Disease
Neuroscience
Medicines
Science
< Back
Science
Science
< Back
Science
Oncology
Rare Disease
Neuroscience
Profiles
Partnering
< Back
Partnering
Therapeutic focus
Meet the team
Clinical Trials
< Back
Clinical Trials
Lay Summaries
Find Clinical Trials
Pipeline
Sustainability
< Back
Sustainability
Sustainability
Environment
Patients
People
Governance
Our Standards
Patients
< Back
Patients
Patients
Together for Oncology
Together for Rare Disease
Together for Neuroscience
Collaborate with us
Stories
Post navigation
Previous
Next
Information relating to compensation elements
Information relating to compensation elements
-
25 May 2022
-
0 mins read
Post navigation
Previous
Next
Related Documents
Ipsen-Information-relating-to-compensation-elements-of-DL-25-mai-2022
(130 KB)
X
You are now leaving the Ipsen group global website. To continue, please click on
Continue
?
